(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Summit Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SMMT's revenue for 2026 to be $20,621,423,615, with the lowest SMMT revenue forecast at $1,886,830,547, and the highest SMMT revenue forecast at $43,189,105,510. On average, 3 Wall Street analysts forecast SMMT's revenue for 2027 to be $63,086,996,466, with the lowest SMMT revenue forecast at $4,754,218,701, and the highest SMMT revenue forecast at $164,377,111,580.
In 2028, SMMT is forecast to generate $885,012,668,087 in revenue, with the lowest revenue forecast at $58,833,456,422 and the highest revenue forecast at $1,843,923,723,105.